TY - JOUR
T1 - Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma
AU - Kawakita, Daisuke
AU - Nagao, Toshitaka
AU - Takahashi, Hideaki
AU - Kano, Satoshi
AU - Honma, Yoshitaka
AU - Hirai, Hideaki
AU - Saigusa, Natsuki
AU - Akazawa, Kohei
AU - Tani, Kaori
AU - Ojiri, Hiroya
AU - Tsukahara, Kiyoaki
AU - Ozawa, Hiroyuki
AU - Okami, Kenji
AU - Kondo, Takahito
AU - Togashi, Takafumi
AU - Fushimi, Chihiro
AU - Shimura, Tomotaka
AU - Shimizu, Akira
AU - Okamoto, Isaku
AU - Okada, Takuro
AU - Imanishi, Yorihisa
AU - Watanabe, Yoshihiro
AU - Otsuka, Kuninori
AU - Sakai, Akihiro
AU - Ebisumoto, Koji
AU - Sato, Yuichiro
AU - Yamazaki, Keisuke
AU - Ueki, Yushi
AU - Hanazawa, Toyoyuki
AU - Saito, Yuki
AU - Ando, Mizuo
AU - Matsuki, Takashi
AU - Nakaguro, Masato
AU - Sato, Yukiko
AU - Urano, Makoto
AU - Utsumi, Yoshitaka
AU - Kohsaka, Shinji
AU - Saotome, Takashi
AU - Tada, Yuichiro
N1 - Publisher Copyright:
© The Author(s), 2022.
PY - 2022
Y1 - 2022
N2 - Background: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent or metastatic (LA/RM) salivary duct carcinoma (SDC) have been reported in prospective studies. However, the survival benefit of these therapies to conventional therapy remains controversial, and whether HER2-targeted therapy or ADT should be chosen in HER2- and androgen receptor (AR)-positive SDC patients remains unknown. Methods: Overall, 323 LA/RM SDC patients treated at seven institutions between August 1992 and June 2020 were retrospectively enrolled. The primary aim was to analyze the effect of HER2-targeted therapy and ADT on overall survival from the diagnosis of LA/RM disease to death from any cause (OS1). The secondary indicators included the overall response rate (ORR), clinical benefit rate (CBR), overall survival from therapy initiation for LA/RM disease (OS2), progression-free survival (PFS), time to second progression (PFS2), duration of response (DoR), and duration of clinical benefit (DoCB) of HER2-targeted therapy or ADT as first-line therapy for HER2-positive/AR-positive SDC. Results: Patients treated with HER2-targeted therapy or ADT had longer OS1 than those treated without these therapies (Median OS1: historical control, 21.6 months; HER2-targeted therapy, 50.6 months; ADT, 32.8 months; HER2-targeted therapy followed by ADT, 42.4 months; and ADT followed by HER2-targeted therapy, 45.2 months, p < 0.001). Among HER2-positive/AR-positive SDC patients, although HER2-targeted therapy had better ORR, CBR, and PFS than those of ADT as first-line therapy, we found no significant differences between HER2-targeted therapy and ADT regarding OS2, PFS2, DoR, and DoCB. Conclusion: Patients treated with HER2-targeted therapy and ADT showed longer survival in LA/RM SDC. HER2-targeted therapy can be recommended prior to ADT for HER2-positive/AR-positive SDC. It is warranted to establish a biomarker that could predict the efficacy of clinical benefit or better response in ADT.
AB - Background: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent or metastatic (LA/RM) salivary duct carcinoma (SDC) have been reported in prospective studies. However, the survival benefit of these therapies to conventional therapy remains controversial, and whether HER2-targeted therapy or ADT should be chosen in HER2- and androgen receptor (AR)-positive SDC patients remains unknown. Methods: Overall, 323 LA/RM SDC patients treated at seven institutions between August 1992 and June 2020 were retrospectively enrolled. The primary aim was to analyze the effect of HER2-targeted therapy and ADT on overall survival from the diagnosis of LA/RM disease to death from any cause (OS1). The secondary indicators included the overall response rate (ORR), clinical benefit rate (CBR), overall survival from therapy initiation for LA/RM disease (OS2), progression-free survival (PFS), time to second progression (PFS2), duration of response (DoR), and duration of clinical benefit (DoCB) of HER2-targeted therapy or ADT as first-line therapy for HER2-positive/AR-positive SDC. Results: Patients treated with HER2-targeted therapy or ADT had longer OS1 than those treated without these therapies (Median OS1: historical control, 21.6 months; HER2-targeted therapy, 50.6 months; ADT, 32.8 months; HER2-targeted therapy followed by ADT, 42.4 months; and ADT followed by HER2-targeted therapy, 45.2 months, p < 0.001). Among HER2-positive/AR-positive SDC patients, although HER2-targeted therapy had better ORR, CBR, and PFS than those of ADT as first-line therapy, we found no significant differences between HER2-targeted therapy and ADT regarding OS2, PFS2, DoR, and DoCB. Conclusion: Patients treated with HER2-targeted therapy and ADT showed longer survival in LA/RM SDC. HER2-targeted therapy can be recommended prior to ADT for HER2-positive/AR-positive SDC. It is warranted to establish a biomarker that could predict the efficacy of clinical benefit or better response in ADT.
UR - http://www.scopus.com/inward/record.url?scp=85139062236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139062236&partnerID=8YFLogxK
U2 - 10.1177/17588359221119538
DO - 10.1177/17588359221119538
M3 - Article
AN - SCOPUS:85139062236
SN - 1758-8340
VL - 14
JO - Therapeutic Advances in Medical Oncology
JF - Therapeutic Advances in Medical Oncology
ER -
